These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1102 related articles for article (PubMed ID: 10966567)

  • 1. Tyrosinase immunoreactivity in fine-needle aspiration samples of metastatic malignant melanoma.
    Fetsch PA; Riker AI; Marincola FM; Abati A
    Cancer; 2000 Aug; 90(4):252-7. PubMed ID: 10966567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosinase immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution.
    Hofbauer GF; Kamarashev J; Geertsen R; Böni R; Dummer R
    J Cutan Pathol; 1998 Apr; 25(4):204-9. PubMed ID: 9609139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T311--an anti-tyrosinase monoclonal antibody for the detection of melanocytic lesions in paraffin embedded tissues.
    Jungbluth AA; Iversen K; Coplan K; Kolb D; Stockert E; Chen YT; Old LJ; Busam K
    Pathol Res Pract; 2000; 196(4):235-42. PubMed ID: 10782467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A).
    Clarkson KS; Sturdgess IC; Molyneux AJ
    J Clin Pathol; 2001 Mar; 54(3):196-200. PubMed ID: 11253130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of tyrosinase mRNA in formalin-fixed, paraffin-embedded archival sections of melanoma, using the reverse transcriptase in situ polymerase chain reaction.
    Guo J; Cheng L; Wen DR; Huang RR; Cochran AJ
    Diagn Mol Pathol; 1998 Feb; 7(1):10-5. PubMed ID: 9646029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution.
    Hofbauer GF; Kamarashev J; Geertsen R; Böni R; Dummer R
    Melanoma Res; 1998 Aug; 8(4):337-43. PubMed ID: 9764809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group.
    de Vries TJ; Smeets M; de Graaf R; Hou-Jensen K; Bröcker EB; Renard N; Eggermont AM; van Muijen GN; Ruiter DJ
    J Pathol; 2001 Jan; 193(1):13-20. PubMed ID: 11169510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution.
    Hofbauer GF; Schaefer C; Noppen C; Böni R; Kamarashev J; Nestle FO; Spagnoli GC; Dummer R
    Am J Pathol; 1997 Dec; 151(6):1549-53. PubMed ID: 9403705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanoma-associated antigen recognized by T cells (MART-1): the advent of a preferred immunocytochemical antibody for the diagnosis of metastatic malignant melanoma with fine-needle aspiration.
    Fetsch PA; Marincola FM; Filie A; Hijazi YM; Kleiner DE; Abati A
    Cancer; 1999 Feb; 87(1):37-42. PubMed ID: 10096358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical identification of canine melanocytic neoplasms with antibodies to melanocytic antigen PNL2 and tyrosinase: comparison with Melan A.
    Ramos-Vara JA; Miller MA
    Vet Pathol; 2011 Mar; 48(2):443-50. PubMed ID: 20858741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development.
    Chen YT; Stockert E; Tsang S; Coplan KA; Old LJ
    Proc Natl Acad Sci U S A; 1995 Aug; 92(18):8125-9. PubMed ID: 7667256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibody MAT-1 against human tyrosinase can detect melanogenic cells on formalin-fixed paraffin-embedded sections.
    Sato N; Suzuki S; Takimoto H; Masui S; Shibata K; Nakano H; Tomita Y
    Pigment Cell Res; 1996 Apr; 9(2):72-6. PubMed ID: 8857669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Semiquantitative assessment of c-erbB-2 (HER-2) status in cytology specimens and tissue sections from breast carcinoma.
    Solomides CC; Zimmerman R; Bibbo M
    Anal Quant Cytol Histol; 1999 Apr; 21(2):121-5. PubMed ID: 10560479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Will PAXgene substitute formalin? A morphological and molecular comparative study using a new fixative system.
    Belloni B; Lambertini C; Nuciforo P; Phillips J; Bruening E; Wong S; Dummer R
    J Clin Pathol; 2013 Feb; 66(2):124-35. PubMed ID: 23125305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma antigen expression in serial fine-needle aspiration samples in patients with metastatic malignant melanoma participating in immunotherapy clinical trials: a preliminary look.
    Fetsch PA; Steinberg SM; Riker AI; Marincola FM; Abati A
    Cancer; 2001 Dec; 93(6):409-14. PubMed ID: 11748581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of formalin fixation time and tissue processing method on immunoreactivity of monoclonal antibody PC10 for proliferating cell nuclear antigen.
    Tahan SR; Wei Y; Ling P; Bistrian BR
    Mod Pathol; 1995 Feb; 8(2):177-82. PubMed ID: 7777480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of the immunodominant regions of the melanoma antigen tyrosinase by anti-tyrosinase monoclonal antibodies.
    Jaanson N; Möll K; Kulla A; Ustav M
    Melanoma Res; 2003 Oct; 13(5):473-82. PubMed ID: 14512789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase.
    Riley JP; Rosenberg SA; Parkhurst MR
    J Immunother; 2001; 24(3):212-20. PubMed ID: 11394498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Routine formaldehyde fixation irreversibly reduces immunoreactivity of Bcl-2 in the nuclear compartment of breast cancer cells, but not in the cytoplasm.
    Hoetelmans RW; van Slooten HJ; Keijzer R; van de Velde CJ; van Dierendonck JH
    Appl Immunohistochem Mol Morphol; 2001 Mar; 9(1):74-80. PubMed ID: 11277419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376.
    Valmori D; Pittet MJ; Vonarbourg C; Rimoldi D; Liénard D; Speiser D; Dunbar R; Cerundolo V; Cerottini JC; Romero P
    Cancer Res; 1999 Aug; 59(16):4050-5. PubMed ID: 10463606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.